Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood test spot pancreatic cancer before it hides behind other pancreatic diseases?

NCT ID NCT07875582

Diagnosis Sponsor: Grigore T. Popa University of Medicine and Pharmacy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 15, 2026 · Last updated Oct 16, 2026 · Updated 1 time

Summary

Pancreatic cancer is hard to catch early because its symptoms overlap with chronic pancreatitis and benign pancreatic cysts. This study asks whether a panel of blood proteins, including GDF-15, ICAM-1, osteopontin, CXCL10, HGF, Nectin-4, periostin, and VEGF-A, can distinguish pancreatic ductal adenocarcinoma from those other conditions. Researchers will compare blood levels across four groups of adults: people with pancreatic cancer, chronic pancreatitis, intraductal papillary mucinous neoplasms, and mucinous cystic neoplasms. They will also test whether combining the proteins with the standard marker CA 19-9 improves accuracy over either approach alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a panel of blood-based protein biomarkers, including GDF-15, ICAM-1, osteopontin, CXCL10, HGF, Nectin-4, periostin, and VEGF-A, measured alongside CA 19-9
What this could lead to
If the panel works, doctors could one day use a simple blood test to flag pancreatic cancer earlier and spare some patients from invasive procedures to rule it out.
What could go wrong
This is an observational study of 100 people, so it can only show whether the markers track with disease, not whether they improve patient outcomes. Biomarker levels can overlap between cancer and benign pancreatic conditions, and the panel may not hold up in larger or more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of patients recruited from two tertiary referral centers in Romania: the Institute of Gastroenterology and Hepatology at Sf. Spiridon County Clinical Emergency Hospital in Iași and Fundeni Clinical Institute in Bucharest. Participants will be prospectively enrolled during routine clinical care in the gastroenterology departments of the participating institutions.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Adults aged 18 years or older * Diagnosis of pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis, intraductal papillary mucinous neoplasm (IPMN), or mucinous cystic neoplasm (MCN) * Histopathological confirmation mandatory for PDAC and optional for benign pancreatic conditions * Diagnosis of benign pancreatic conditions confirmed by imaging criteria and/or a minimum clinical follow-up of 12 months * Written informed consent Exclusion criteria: * Less than 3 months since resolution of the most recent episode of acute pancreatitis * Other active malignancies * Severe systemic inflammatory diseases * Oncological treatment initiated before blood sample collection, including chemotherapy or surgical resection * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pancreatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic pancreatitis malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic intraductal papillary-mucinous neoplasm pancreatic mucinous-cystic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pancreatitis Intraductal papillary mucinous neoplasm Mucinous cystic neoplasm Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Saint Spiridon Emergency County Hospital

    RECRUITING

    Iași, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.